08.25.25 -- Biopharma Manufacturing Outsourcing Is Flexible, Not Fractured

Discover how Nanoform's patented Bio platform is revolutionizing biologics and peptide delivery. In this webinar, explore two breakthrough case studies—subcutaneous Trastuzumab with improved stability and syringeability, and inhalable Semaglutide for deep lung delivery. Learn how these innovations can boost patient comfort, compliance, and outcomes. Don’t miss insights shaping the future of patient-friendly therapies. Click here to learn more.

By prioritizing the management of Out of Expectation (OOX) results within your CDMO laboratory, learn how you can ensure product integrity, patient safety, and unwavering regulatory compliance.

Ready to ensure your facilities, systems, and teams are prepared for success? Discover a proven framework to accelerate operational readiness, mitigate risks, and achieve sustainable results.

Review a study showcasing the successful application of miniaturized biochemical assays to screen a diverse range of drug candidates against multiple target molecules.

Transferring cell-based assays for biologics starts with defining operator and equipment parameters, positive and negative controls, and a sufficient dynamic range.

Gain expert insights on how tailored approaches and innovative technologies enable fast and flexible development workflows, ultimately supporting rapid therapeutic breakthroughs.

As autoinjectors evolve to accommodate a diverse array of chronic diseases, consider the impact of partnering with experienced device manufacturers and fill/finish providers.

Would changing the ASD particle structure and lowering drug load improve outcomes? Learn how one solid dispersion technology lowered pill burdens and demonstrated an improved therapeutic response.

Experienced outsourcing partners will have the right facility and technical capabilities, a culture of speed and execution, and shared expectations and commitment to continuous improvement.

Accelerate your path from discovery to clinic by leveraging high-quality plasmid DNA, optimized expression systems, and early developability assessments to streamline transient protein production.

ADCs have proven to be highly effective in cancer treatment, but their manufacturing poses challenges. Learn how a CDMO partner can help bring these treatments to patients safely and efficiently.

Delve into the details of this straightforward approach to maximize yields early in development, leveraging vaccine expertise, robust platforms, and Vero and Quail cell lines.

This Lonza webinar explores the development of multi-specific biotherapeutics, which offer enhanced efficacy but pose manufacturing challenges. Lonza’s toolbox approach—featuring in silico developability screening, vector design, the GS Gene Expression System®, and immune cell assays—enables early risk assessment of manufacturability and immunosafety. This helps streamline candidate selection and accelerate timelines into clinical development. Click here to learn more.

Uncover how accurate detection of toxic double-stranded RNA impurities is critical in mRNA drug development, and expert ELISA-based solutions that support safe, effective therapeutic release.

By leveraging our proprietary non-viral gene insertion technology, GPEx® Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics.

Explore why our partners trust us to produce safe, high-quality injectable pharmaceuticals, and where the company plans to head next.

Discover on-site managed laboratory and manufacturing services, covering everything from R&D to QC, method development, and regulatory support, without headcount or compliance burdens.

As a fully integrated CDMO, we offer a comprehensive suite of services, from early-stage research to robust commercial manufacturing, within our state-of-the-art facilities.

Our drug product manufacturing services provide the features you need to protect your high-value drug substance. Fully-automated filling within SKAN isolators meets stringent regulatory requirements.